UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study
May 02, 2019 at 13:41 PM EDT
British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.